Parkinson´s disease (PD) is aneurodegenerative disorder that results from a progressive dopaminergicneuronal loss. It is considered a multifactorial condition due to themultiplicity of symptoms experienced by patients. While this condition is knownfor its characteristic motor deficits, patients also havewide variety of non-motor symptoms, such as impaired learning and memorydeficits, which severely affect their quality of life. Thesenon-motor symptoms result from the dysfunction of interconnected systems,including the striatum, the neocortex and the hippocampus. Growthfactors are new targets for therapeutical approaches. Insulin-like growthfactor-1 (IGF-1) is an endogenous peptide transported acrossthe blood brain barrier that is protective in several brain injury models,including in an animal model of parkinsonism.